CREBBP is a Novel Biomarker for Diagnostic and Prognostic of Patients with Renal Cell Carcinoma

As an important transcription co-regulator, CREBBP played important roles in gene transcription and signal transduction. It had been reported that its low expression was closely related to cancer progression. We explored the roles of CREBBP expression among renal cell carcinoma in order to clarify its potential clinical application value in the diagnosis, pathological process and patients prognosis. In the present study, we found that CREBBP expression was reduced in renal cell carcinoma compared with normal tissues, and its expression was negatively correlated with tumor progression. Furthermore, lower CREBBP expression in dead than survival patients, and it had good clinical diagnostic value in renal cell carcinoma. The OS and RFS of patients with low CREBBP expression were significantly shortened, and it was a dependent predictor for poor prognosis. Additionally, we also found the reactive oxygen species pathway, DNA repair and myc-targets V2 signaling were significantly enriched in the low CREBBP expression phenotype. In conclusion, low CREBBP expression could be regarded as a prognosis biomarker and potential therapeutic target for renal cell carcinoma.